Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel in Asymptomatic Melanoma Brain Metastases
NCT05640193Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2022
- Primary completion
- Nov 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lifileucel in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility of treatment with LN-144 at 1 year. Started Nov 2022; status: active, not recruiting.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05640193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640193.